Conference Proceedings

KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER /HER2-) breast cancer.

Fatima Cardoso, Aditya Bardia, Fabrice Andre, David W Cescon, Heather L McArthur, Melinda L Telli, Sherene Loi, Javier Cortes, Peter Schmid, Nadia Harbeck, Carsten Denkert, Christian Jackisch, Liyi Jia, Kim M Hirshfield, Vassiliki Karantza

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2019